Protagonist Therapeutics
PTGX · Nasdaq · United States
Share price · PTGX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PTGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Aug 2026+6.5%
- 17 Jul 2026+6.7%
Nothing announced by PTGX that day or the session before.
- 7 Jul 2026+7.1%
Nothing announced by PTGX that day or the session before.
- 9 Jun 2026+8.0%
Nothing announced by PTGX that day or the session before.
- 4 Jun 2026+7.7%
Nothing announced by PTGX that day or the session before.
- 11 May 2026+4.2%
Nothing announced by PTGX that day or the session before.
- 28 Apr 2026+2.7%
Nothing announced by PTGX that day or the session before.
- 14 Apr 2026+7.3%
Nothing announced by PTGX that day or the session before.
- 19 Mar 2026+4.7%
- Day beforeJohnson & Johnson: FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptideJNJ +0.1%
- 27 Feb 2026+4.2%
Nothing announced by PTGX that day or the session before.
Share of unusual movement by asset
For each asset, the share of PTGX's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
icotrokinra(Icotyde) | Approved | IL-23 receptorPeptide | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease |
| Approved | FerroportinPeptide | Polycythemia Vera |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $41M | $499M+ $302M short-term inv. | —-$23M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $42M | $420M+ $363M short-term inv. | —$219M operating cash flow | report ↗ |
| 2026-Q1 | $56M | $47M | $194M+ $354M short-term inv. | —-$49M operating cash flow | report ↗ |
| 2025-Q3 | $4.7M | $40M | $114M+ $462M short-term inv. | $39M-$1.9M operating cash flow | report ↗ |
| 2025-Q2 | $5.5M | $37M | $169M+ $402M short-term inv. | $35M-$29M operating cash flow | report ↗ |
| 2025-Q1 | $28M | $36M | $140M+ $435M short-term inv. | $12M$125M operating cash flow | report ↗ |
| 2024-Q3 | $4.7M | $36M | $131M+ $338M short-term inv. | $33M-$28M operating cash flow | report ↗ |
| 2024-Q2 | $4.2M | $34M | $356M+ $208M short-term inv. | $31M$269M operating cash flow | report ↗ |
| 2024-Q1 | $255M | $34M | $173M+ $150M short-term inv. | —-$27M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $31M | $231M+ $90M short-term inv. | $34M-$27M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $33M | $236M+ $78M short-term inv. | $38M-$26M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $27M | $128M+ $103M short-term inv. | $34M-$34M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $25M | $153M+ $115M short-term inv. | $31M-$25M operating cash flow | report ↗ |
| 2022-Q2 | $0.9M | $35M | $120M+ $172M short-term inv. | $41M-$14M operating cash flow | report ↗ |
| 2022-Q1 | $26M | $36M | $99M+ $207M short-term inv. | $21M-$38M operating cash flow | report ↗ |
| 2021-Q3 | $10M | $37M | $121M+ $194M short-term inv. | $34M-$28M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $46M | $159M | $129M+ $439M short-term inv. | $33M$58M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $434M | $138M | $97M+ $322M short-term inv. | —$184M operating cash flow | report ↗ |
| 2023-FY | $60M | $120M | $187M+ $155M short-term inv. | $20M-$70M operating cash flow | report ↗ |
| 2022-FY | $27M | $126M | $126M+ $112M short-term inv. | $32M-$108M operating cash flow | report ↗ |
| 2021-FY | $27M | $126M | $124M+ $203M short-term inv. | $31M-$108M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 37 sales ($95.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | MOLINA ARTURO MD · Chief Medical Officer | Open-market sale | 2,718 | $124.65 | $339K | Form 4 |
| 2026-09-30 | Ali Asif · Chief Financial Officer | Option exercise | 9,229 | $38.98 | $360K | Form 4 |
| 2026-09-30 | Ali Asif · Chief Financial Officer | Option exercise | 28,438 | $23.42 | $666K | Form 4 |
| 2026-09-30 | Ali Asif · Chief Financial Officer | Option exercise | 15,650 | $19.19 | $300K | Form 4 |
| 2026-09-30 | Ali Asif · Chief Financial Officer | Option exercise | 5,312 | $12.17 | $65K | Form 4 |
| 2026-09-30 | Ali Asif · Chief Financial Officer | Open-market sale | 12,595 | $141.77 | $1.8M | Form 4 |
| 2026-09-30 | Ali Asif · Chief Financial Officer | Open-market sale | 46,034 | $141.78 | $6.5M | Form 4 |
| 2026-09-30 | Ali Asif · Chief Financial Officer | Option exercise (derivative) | 9,229 | — | — | Form 4 |